Atrium Therapeutics, Inc. (RNA)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on RNA

With Tiblio's Option Bot, you can configure your own wheel strategy including RNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Avidity Biosciences to Participate in Upcoming Investor Conferences
RNA
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral

SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00 p.m.

Read More
image for news Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral

SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,000 shares of its common stock and 53,500 restricted stock units ("RSUs") to twenty-two (22) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees …

Read More
image for news Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

About Atrium Therapeutics, Inc. (RNA)

  • IPO Date 2026-02-27
  • Website http://www.atriumtherapeutics.com
  • Industry Biotechnology
  • CEO Kathleen Gallagher
  • Employees None
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.